MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-07-2024
Chimerix Market Cap 2011-2026 | CMRX
As of January 05, 2026 Chimerix has a market cap of $ 756 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Chimerix
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104 M | 147 M | 546 M | 300 M | 94.9 M | 116 M | 225 M | 237 M | 338 M | 1.32 B | 385 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.32 B | 94.9 M | 347 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K |  USA |
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Pharming Group N.V.
PHAR
|
5.94 B | $ 17.07 | -1.28 % | $ 7.59 B |  Niderland |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.32 | 7.79 % | $ 7.99 B |  Australia |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Immutep Limited
IMMP
|
1.95 B | $ 2.9 | 1.22 % | $ 1.08 B | Australia |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 0.21 | 5.66 % | $ 457 M |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 212.56 | -0.32 % | $ 5 B |  Danmark |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 10.81 | -4.21 % | $ 699 M | USA |
 |
Aclaris Therapeutics
ACRS
|
152 M | $ 2.88 | -4.26 % | $ 223 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Anika Therapeutics
ANIK
|
373 M | $ 9.41 | -2.08 % | $ 138 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 96.62 | 1.49 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 26.33 | -1.68 % | $ 1.28 B | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.9 | -4.5 % | $ 485 M | Britain |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
BioVie
BIVI
|
2.44 M | $ 1.34 | 15.52 % | $ 1.98 M | USA |
 |
Axon Enterprise
AXON
|
39.8 B | $ 563.06 | -0.86 % | $ 42.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.78 | 6.92 % | $ 17.5 M | USA |
 |
AstraZeneca PLC
AZN
|
81.2 B | $ 91.64 | -0.32 % | $ 96.9 B | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 8.76 | -1.79 % | $ 1.47 B | Britain |
 |
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | USA |
 |
Biogen
BIIB
|
19.3 B | $ 177.33 | 0.76 % | $ 25.8 B | USA |
 |
Abeona Therapeutics
ABEO
|
149 M | $ 5.28 | 0.27 % | $ 113 M | USA |
 |
ADiTx Therapeutics
ADTX
|
59.2 K | $ 0.86 | 3.31 % | $ 11.3 K | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | $ 4.66 | 3.1 % | $ 867 M | Germany |